» Articles » PMID: 34055049

Risk Factors for Positive Sentinel Lymph Node, Lymphatic or Hematogenous Dissemination over Time in Patients with Cutaneous Melanoma

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2021 May 31
PMID 34055049
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present study was to assess the influence of localization, age or sex and histopathological characteristics upon the chance of developing lymphatic or hematogenous metastatic spread over time, or a positive sentinel lymph node in cutaneous melanoma patients. Patients from the Department of Dermatology, County Emergency Hospital Cluj-Napoca (Cluj-Napoca, Romania), presenting with cutaneous melanoma confirmed histopathologically and a SPECT/CT or lymphoscintigraphic examination to detect the sentinel lymph node, were included in the present study. Our results revealed that Breslow index >2 mm [odds ratio (OR)=4.22, 95% confidence interval (CI) (1.12; 15.93)], presence of ulceration [OR=6.01, 95% CI (1.87; 19.35)], and positive sentinel lymph node [for at least one sentinel lymph node OR=3.58, 95% CI (1.06; 12.04)] were risk factors for hematogenous metastases. All these, except for the Breslow index >2 mm, were demonstrated to be a risk factor for lymphatic spread metastases over time. Ulceration and male sex also represented risk factors for a positive sentinel lymph node, men having a higher risk of developing sentinel lymph nodes than women [adjusted OR=2.27, 95% CI (1.00; 5.13)]. In conclusion, the predictors that influence the occurrence of lymphatic or hematogenous metastases may differ, ulceration and positive sentinel lymph node being common for both types of metastatic spread, while Breslow index being a significant predictor only for hematogenous metastases. Male sex and the presence of ulceration were demonstrated to be significant risk factors for positive sentinel lymph nodes.

Citing Articles

Risk Prediction Models for Sentinel Node Positivity in Melanoma: A Systematic Review and Meta-Analysis.

Ma B, Gandhi M, Czyz S, Jia J, Rankin B, Osman S JAMA Dermatol. 2025; .

PMID: 40072444 PMC: 11904803. DOI: 10.1001/jamadermatol.2025.0113.


Skin Cancer Research Goes Digital: Looking for Biomarkers within the Droplets.

Dobre E, Constantin C, Neagu M J Pers Med. 2022; 12(7).

PMID: 35887633 PMC: 9323323. DOI: 10.3390/jpm12071136.

References
1.
Cherobin A, Wainstein A, Colosimo E, Goulart E, Bittencourt F . Prognostic factors for metastasis in cutaneous melanoma. An Bras Dermatol. 2018; 93(1):19-26. PMC: 5871357. DOI: 10.1590/abd1806-4841.20184779. View

2.
Calomarde-Rees L, Garcia-Calatayud R, Requena Caballero C, Manrique-Silva E, Traves V, Garcia-Casado Z . Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma. JAMA Dermatol. 2019; 155(6):679-687. PMC: 6495361. DOI: 10.1001/jamadermatol.2019.0069. View

3.
Callender G, Egger M, Burton A, Scoggins C, Ross M, Stromberg A . Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker. Am J Surg. 2011; 202(6):659-64. DOI: 10.1016/j.amjsurg.2011.06.048. View

4.
Abdel-Rahman O . Clinical correlates and prognostic value of different metastatic sites in patients with malignant melanoma of the skin: a SEER database analysis. J Dermatolog Treat. 2017; 29(2):176-181. DOI: 10.1080/09546634.2017.1360987. View

5.
Rotaru M, Jitian C, Iancu G . A 10-year retrospective study of melanoma stage at diagnosis in the academic emergency hospital of Sibiu county. Oncol Lett. 2019; 17(5):4145-4148. PMC: 6444339. DOI: 10.3892/ol.2019.10098. View